Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Go back to Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 11.42 +0.24 (2.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.18 | 52 Week High | $1.45 | |||
| Open | $10.88 | 52 Week Low | $0.50 | |||
| Day High | $12.23 | P/E | N/A | |||
| Day Low | $10.86 | EPS | $0.00 | |||
| Volume | 2,963,972 | |||||
